Viz.ai’s Viz Neuro Suite Evaluated in Three Real-World Studies

July 31, 2023—Viz.ai announced findings from three new studies of the real-world impact of the Viz Neuro Suite. The findings demonstrate the clinical, health equity, and patient benefits of artificial intelligence (AI)–driven technology, noted the company. The AI-powered Viz platform is an intelligent care coordination solution that identifies patients with a particular disease, informs critical decisions at the point of care, and optimizes care pathways to help improve outcomes.

The abstracts were presented at the SNIS 2023, the Society of NeuroInterventional Surgery’s 20th annual meeting held July 31 to August 4 in San Diego, California.

First, a study from HCA Houston Healthcare, “Viz LVO versus Rapid LVO (RapidAI) in Detection of Large Vessel Occlusion on CT Angiography for Acute Stroke,” by Adam Delora, MD, et al, highlighted the superior performance of the Viz LVO solution in detecting suspected large vessel occlusion on CTA for acute stroke. The findings underscore the role of Viz.ai’s AI algorithms in accurately identifying and triaging patients for prompt intervention, ultimately improving outcomes and saving lives.

“Accurate early detection of stroke using the Viz.ai stroke platform significantly improved our team communication and resulted in improved overall stroke metrics,” commented study investigator Mohamad Ezzeldin, MD, in the company’s press release. “The Viz.ai platform has become an invaluable tool in our practice, and I rely on it when I’m on call.”

Dr. Ezzeldin is a neurointerventional surgeon, Director of CNS Neuroendovascular Surgery, and Stroke Medical Director for HCA Houston Healthcare Kingwood in Kingwood, Texas. HCA Healthcare has a minority equity stake in Viz.ai and purchases products from the company for use in its facilities, advised the company.

The second abstract, “Rural Versus Metropolitan Stroke Activation Incidence: Using Viz.ai To Determine Disease Penetrance,” by lead investigator Justin Fraser, MD, et al from the University of Kentucky in Lexington, Kentucky, demonstrated the value of data to visualize the level of disparities in care and redistribute resources to increase access to stroke care in rural areas. By leveraging AI technology, Viz.ai was shown to enable health care providers to bridge geographical gaps, ensuring equitable access to time-critical interventions for stroke patients, regardless of their location.

“Rural areas of Kentucky—particularly in Appalachia—are known to have increased risk factors for major diseases,” commented Dr. Fraser in Viz.ai’s press release. “We are using this technology as a bridge into local communities with high incidences of stroke. These findings provide confirmation of the importance of stroke care protocols in rural areas and the value of fast identification and triage for these communities.”

The third abstract titled “Radiographic and Clinical Outcome-Based Assessment of Middle Meningeal Artery Embolization for Chronic Subdural Hematoma Patients at a Community Hospital,” by Dorothea Altschul, MD, et al evaluated the implementation of Viz.ai’s AI-powered solutions to assess and treat chronic subdural hematoma patients in Valley Health System of northern New Jersey and southern New York.

According to the company, the data showed that by enabling precise radiographic analysis and clinical outcome assessment, Viz.ai empowers community hospitals to deliver enhanced care to patients with this complex condition.

“It was remarkable to have the ability to educate patients about their disease at the bedside and show patients their scans with volume measurements,” commented Dr. Altschul, who is Director of Neuroendovascular Surgery at Valley Health System in Ridgewood, New Jersey. “We used this tool not only for care coordination but also for care education.”